 LONDON and REDWOOD CITY, Calif., Dec. 15, 2020 GLOBE NEWSWIRE -- Mereo BioPharma Group plc NASDAQ: MREO, AIM: MPH Mereo or the Company, a clinical stage biopharmaceutical company focused on oncology and rare diseases, today provided a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM and the continued listing of its ADSs on Nasdaq, as originally announced on November 11, 2020. 